Government Accountability Project v. U.S. Department of Health & Human Services

568 F. Supp. 2d 55, 2008 U.S. Dist. LEXIS 59135, 2008 WL 2952212
CourtDistrict Court, District of Columbia
DecidedAugust 4, 2008
DocketCivil 07-1702 (CKK)
StatusPublished
Cited by12 cases

This text of 568 F. Supp. 2d 55 (Government Accountability Project v. U.S. Department of Health & Human Services) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Government Accountability Project v. U.S. Department of Health & Human Services, 568 F. Supp. 2d 55, 2008 U.S. Dist. LEXIS 59135, 2008 WL 2952212 (D.D.C. 2008).

Opinion

MEMORANDUM OPINION

COLLEEN KOLLAR-KOTELLY, District Judge.

The above-captioned case arises out of a request filed by Plaintiff, Government Accountability Project (“GAP”) pursuant to the Freedom of Information Act (“FOIA”), 5 U.S.C. § 552 et seq., seeking the disclosure and release of agency records consisting of clinical study data regarding the drug Ciprofloxacin (“Cipro”). After Plaintiff’s FOIA request had been pending for eight months with no response, Plaintiff filed a Motion for Judgment on the Pleadings. Defendants, the United States Department of Health and Human Services (“HHS”) and the United States Food and Drug Administration (“FDA”), oppose Plaintiffs motion and have filed their own motion for a stay pursuant to Open America v. Watergate Special Prosecution, 547 F.2d 605 (D.C.Cir.1976). Defendants seek to stay the proceedings in this action until August 15, 2009 in order to allow Defendants to complete their review and release the documents responsive to Plaintiffs request. Plaintiff opposes Defendants’ motion for a stay. The Court has thoroughly reviewed Plaintiffs [5] Motion for Judgment on the Pleadings, Defendants’ [7] Motion for an Open America Stay, supporting declarations and attached exhibits, Plaintiffs Opposition to Defendants’ motion and Reply in support of its own motion, and Defendants’ Reply in support of their motion, as well as the relevant statutes and case law. Based upon the foregoing, the Court concludes that Defendants have failed to demonstrate exceptional circumstances and due diligence sufficient to justify the stay they seek. Accordingly, the Court shall DENY Defendants’ [7] Motion for Open America Stay and shall GRANT-IN-PART Plaintiffs [5] Motion for Judgment on the Pleadings insofar as it seeks a judgment that Defendants are required to process Plaintiffs FOIA request and release the documents on a rolling basis.

Although the Court concludes that Defendants have not established exceptional circumstances sufficient to warrant the eighteen-month stay they seek, the Court recognizes that Defendants are faced with a substantial backlog of pending FOIA requests and that Plaintiffs request is currently pending in the processing queue. Therefore, as set forth in the Order accom *57 panying this Memorandum Opinion, the Court shall require Defendants to file a status report with the Court on or before September 5, 2008, advising the Court as to the volume of the requested records, where Plaintiffs FOIA request currently stands in the processing queue, i.e., the date by which Defendants expect to begin processing Plaintiffs FOIA request, and how long they expect it will take to process Plaintiffs request, so that the Court can set an appropriate processing schedule.

I. BACKGROUND

Plaintiff Government Accountability Project is a non-profit advocacy organization that frequently requests access to agency records. Compl. ¶ 3. On June 27, 2007, GAP submitted a FOIA request to the FDA, seeking records of clinical studies regarding Ciprofloxacin. Id. ¶ 5. Specifically, GAP requested “[a]ll goniometry (joint angle motion measurement) data ... pertaining to domestic and foreign clinical trial studies 1001169 and 100201” and “all FDA Division of Scientific Investigations (“DSI”) reports and records, domestic and outside of US, concerning all DSI inspections pertaining to clinical trial studies 1001169 and 100201.” Compl. ¶ 6.

By letter dated June 28, 2007, the FDA acknowledged receipt of GAP’s FOIA request. Compl. ¶ 7. The FDA forwarded GAP’s request to the Division of Information Policy Disclosure (“DIDP”), of the Center for Drug Evaluation and Research (“CDER”). 2/4/08 Deck of Frederick J. Sadler (hereinafter “Sadler Deck”) ¶ 12. CDER regulates Cipro, and was therefore determined to be most likely to have responsive documents. Id. DIDP comprises 28 full-time employees and two full-time contractors. 2/4/08 Deck of Nancy B. Sager (hereinafter “Sager Deck”) ¶ 6. In processing FOIA requests, the CDER utilizes two processing tracks. Id. ¶ 8. CDER assigns requests to the “Simple Track” when the records “do not require DIDP personnel to redact documents, ... the documents requested are publicly available, or it is apparent from the face of the request that the documents do not exist in CDER’s records.” Id. ¶ 9. When records are not readily available, CDER assigns FOIA requests to the slower “Complex Track.” Id. ¶ 8. DIDP personnel generally process requests within each track on a first-in, first-out basis. 1 Id. Because the records GAP requested were not readily available and will likely require redaction and review once located, DIDP assigned GAP’s request to the Complex Track. Id. ¶¶ 29-33.

Defendants have not provided a detailed estimate of when they anticipate GAP’s FOIA request will be processed, nor have they provided an estimate as to the number of records likely to be responsive to GAP’s request. Instead, Ms. Sager, the Director of DIDP, asserts that, “based on DIDP’s current backlog and current processing time for requests seeking this type of information,” “DIDP estimates that [GAP’s] request will move to the head of the Complex Track approximately 16 months from the date of [Ms. Sager’s] Declaration,” i.e., in June 2009. Id. ¶ 29. Ms. Sager further avers that “[i]t is impossible for DIDP to estimate precisely at this time the volume of responsive documents likely to be identified during the searches for this request.... However, in light of DIDP’s experience with requests seeking *58 similar types of information, DIDP estimates that it will require two months to process plaintiffs FOIA request once it rises to the head of the Complex Track.” Sager Decl. ¶ 30.

GAP did not receive any documents responsive to its FOIA request within the 20-working-day time frame mandated by the FOIA, and filed an appeal of the constructive denial of its FOIA request with the FDA’s Freedom of Information Office on August 3, 2007. Compl. ¶¶ 8-10. By letter dated August 6, 2007, -HHS Public Health Service acknowledged receipt of GAP’s appeal, but GAP has not received any information regarding the status of its appeal since then. Id. ¶ 11. On September 25, 2007, GAP filed its Complaint in this action. Id. ¶ 13. On January 29, 2008, GAP filed its Motion for Judgment on the Pleadings.

In response, on February 19, 2008, Defendants filed their Motion for an Open America Stay and Opposition to Plaintiffs Motion for Judgment on the Pleadings. According to Defendants, as of the date of that Motion, GAP’s request remained pending in DIDP’s Complex Track processing queue. Defs.’ Mot. for an Open America Stay (hereinafter “Defs.’ Mot.”) at 4. Both Plaintiffs Motion for Judgment on the Pleadings and Defendants’ Motion for an Open America Stay are now ripe for review.

II. DISCUSSION

A. Legal Standard

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
568 F. Supp. 2d 55, 2008 U.S. Dist. LEXIS 59135, 2008 WL 2952212, Counsel Stack Legal Research, https://law.counselstack.com/opinion/government-accountability-project-v-us-department-of-health-human-dcd-2008.